Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

HL-A antigens and multiple sclerosis.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Gustatory Dysfunction in Multiple Sclerosis
Risk factors for rare diseases can be risky to define: PML and natalizumab.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Alerting Network Dysfunction in Early Multiple Sclerosis.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Mitochondrial approaches for neuroprotection.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.

Pages